Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients

about

Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients

Item

http://www.wikidata.org/entity/Q37191051

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 December 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients

@en

Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients.

@nl

type

Item

label

Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients

@en

Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients.

@nl

prefLabel

Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients

@en

Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients.

@nl

P1476

Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients

@en

P2093

Jasmeet Chadha Singh

http://www.w3.org/2001/XMLSchema#string

P2860

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Cardiac dysfunction in the trastuzumab clinical trials experience

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

P2888

s40266-015-0326-1

P304

975-982

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40266-015-0326-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stuart M Lichtman

P577

2015-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26645293

http://www.w3.org/2001/XMLSchema#string

P932

4991772

http://www.w3.org/2001/XMLSchema#string